180 related articles for article (PubMed ID: 36724301)
21. Safety and Efficacy of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 2 Diabetes: From Injections to Hybrid Closed-Loop Therapy.
Davis GM; Peters AL; Bode BW; Carlson AL; Dumais B; Vienneau TE; Huyett LM; Ly TT
Diabetes Care; 2023 Apr; 46(4):742-750. PubMed ID: 36787903
[TBL] [Abstract][Full Text] [Related]
22. Glycemic control metrics in a cohort of hospitalized patients with type 1 diabetes using hybrid closed-loop and advanced hybrid closed-loop systems.
Gómez Medina AM; Henao-Carrillo DC; Yepes C; Silva J; Gómez González JA; Cortes D; Robledo S; Mejía G; Rondon M
Diabetes Res Clin Pract; 2023 Oct; 204():110897. PubMed ID: 37678728
[TBL] [Abstract][Full Text] [Related]
23. Time In Range in Children with Type 1 Diabetes Using Treatment Strategies Based on Nonautomated Insulin Delivery Systems in the Real World.
Cherubini V; Bonfanti R; Casertano A; De Nitto E; Iannilli A; Lombardo F; Maltoni G; Marigliano M; Bassi M; Minuto N; Mozzillo E; Rabbone I; Rapini N; Rigamonti A; Salzano G; Scaramuzza A; Schiaffini R; Tinti D; Toni S; Zagaroli L; Zucchini S; Maffeis C; Gesuita R
Diabetes Technol Ther; 2020 Jul; 22(7):509-515. PubMed ID: 32073311
[No Abstract] [Full Text] [Related]
24. Rapid Improvement in Time in Range After the Implementation of an Advanced Hybrid Closed-Loop System in Adolescents and Adults with Type 1 Diabetes.
Beato-Víbora PI; Gallego-Gamero F; Ambrojo-López A; Gil-Poch E; Martín-Romo I; Arroyo-Díez FJ
Diabetes Technol Ther; 2021 Sep; 23(9):609-615. PubMed ID: 33784187
[No Abstract] [Full Text] [Related]
25. Advanced Hybrid Closed-Loop System Achieves and Maintains Recommended Time in Range Levels for Up To 2 Years: Predictors of Best Efficacy.
Lepore G; Borella ND; Castagna G; Ippolito S; Bonfadini S; Corsi A; Scaranna C; Dodesini AR; Bellante R; Trevisan R
Diabetes Technol Ther; 2024 Jan; 26(1):49-58. PubMed ID: 37902785
[No Abstract] [Full Text] [Related]
26. Glycometabolic outcomes in adult type 1 diabetic patients switching to closed-loop systems.
Papa G; Cannarella R; Condorelli RA; Finocchiaro C; Calogero AE; La Vignera S
Diabetes Res Clin Pract; 2023 Oct; 204():110907. PubMed ID: 37708979
[TBL] [Abstract][Full Text] [Related]
27. Continuous Glucose Monitoring in Adults with Type 1 Diabetes: Real-World Data from the German/Austrian Prospective Diabetes Follow-Up Registry.
Sandig D; Grimsmann J; Reinauer C; Melmer A; Zimny S; Müller-Korbsch M; Forestier N; Zeyfang A; Bramlage P; Danne T; Meissner T; Holl RW
Diabetes Technol Ther; 2020 Aug; 22(8):602-612. PubMed ID: 32522039
[No Abstract] [Full Text] [Related]
28. MiniMed 780G Advanced Hybrid Closed-Loop System Outcomes According to Pubertal Status: Awesome Study Group Real-Life Experience.
Rachmiel M; Lebenthal Y; Mazor-Aronovitch K; Brener A; Levek N; Jacobi-Polishook T; Ben Ari T; Abiri S; Landau Z; Pinhas-Hamiel O
Diabetes Technol Ther; 2023 Sep; 25(9):643-651. PubMed ID: 37219952
[No Abstract] [Full Text] [Related]
29. Real-world outcomes with different technology modalities in type 1 diabetes.
Beato-Víbora PI; Gallego-Gamero F; Ambrojo-López A
Nutr Metab Cardiovasc Dis; 2021 Jun; 31(6):1845-1850. PubMed ID: 33838993
[TBL] [Abstract][Full Text] [Related]
30. Closed-Loop Insulin Therapy in Older Adults with Type 1 Diabetes: Real-World Data.
Toschi E; Atakov-Castillo A; Slyne C; Munshi M
Diabetes Technol Ther; 2022 Feb; 24(2):140-142. PubMed ID: 34609917
[No Abstract] [Full Text] [Related]
31. Glycaemia in low-premixed insulin analogue type 2 diabetes patients in a real-world setting: are the CGM targets met?
Krajnc M; Kravos Tramšek NA
Eur J Med Res; 2023 Mar; 28(1):111. PubMed ID: 36882852
[TBL] [Abstract][Full Text] [Related]
32. Performance of an Automated Insulin Delivery System: Results of Early Phase Feasibility Studies.
Christiansen M; Bartee A; Lalonde A; Jones RE; Katz M; Wolpert H; Brazg R
Diabetes Technol Ther; 2021 Mar; 23(3):187-194. PubMed ID: 32940537
[No Abstract] [Full Text] [Related]
33. Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial.
McAuley SA; Lee MH; Paldus B; Vogrin S; de Bock MI; Abraham MB; Bach LA; Burt MG; Cohen ND; Colman PG; Davis EA; Hendrieckx C; Holmes-Walker DJ; Kaye J; Keech AC; Kumareswaran K; MacIsaac RJ; McCallum RW; Sims CM; Speight J; Stranks SN; Sundararajan V; Trawley S; Ward GM; Jenkins AJ; Jones TW; O'Neal DN;
Diabetes Care; 2020 Dec; 43(12):3024-3033. PubMed ID: 33055139
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and Safety of an Advanced Hybrid Closed-Loop System in Adolescents and Adults with Type 1 Diabetes Previously Treated with Continuous Subcutaneous Insulin Infusion and Flash Glucose Monitoring.
Gros Herguido N; Amuedo S; Bellido V; López Gallardo G; Losada F; Pérez Morales A; Ruiz Trillo CA; Soto Moreno A
Diabetes Technol Ther; 2023 Feb; 25(2):151-156. PubMed ID: 36108305
[TBL] [Abstract][Full Text] [Related]
35. Less Nocturnal Hypoglycemia but Equivalent Time in Range Among Adults with Type 1 Diabetes Using Insulin Pumps Versus Multiple Daily Injections.
McAuley SA; Vogrin S; Lee MH; Paldus B; Trawley S; de Bock MI; Abraham MB; Bach LA; Burt MG; Cohen ND; Colman PG; Davis EA; Hendrieckx C; Holmes-Walker DJ; Jenkins AJ; Kaye J; Keech AC; Kumareswaran K; MacIsaac RJ; McCallum RW; Sims CM; Speight J; Stranks SN; Sundararajan V; Ward GM; Jones TW; O'Neal DN;
Diabetes Technol Ther; 2021 Jun; 23(6):460-466. PubMed ID: 33351699
[No Abstract] [Full Text] [Related]
36. Retrospective Analysis of 3-Month Real-World Glucose Data After the MiniMed 670G System Commercial Launch.
Stone MP; Agrawal P; Chen X; Liu M; Shin J; Cordero TL; Kaufman FR
Diabetes Technol Ther; 2018 Oct; 20(10):689-692. PubMed ID: 30160523
[TBL] [Abstract][Full Text] [Related]
37. Assessment of Patient-reported Satisfaction and Metabolic Outcomes Following Initiation of the Second Generation of Flash Glucose Monitoring in Patients with Type 1 Diabetes.
Al Hayek A; Robert AA; Alzahrani WM; Al Dawish MA
Curr Diabetes Rev; 2024; 20(4):e100823219628. PubMed ID: 37563819
[TBL] [Abstract][Full Text] [Related]
38. Outcomes in Pump- and CGM-Baseline Use Subgroups in the International Diabetes Closed-Loop Trial.
Ekhlaspour L; Raghinaru D; Forlenza GP; Isganaitis E; Kudva YC; Lam DW; Levister C; O'Malley G; Church MM; Lum JW; Buckingham B; Brown SA
J Diabetes Sci Technol; 2023 Jul; 17(4):935-942. PubMed ID: 35473359
[TBL] [Abstract][Full Text] [Related]
39. Switching from treatment with sensor augmented pump to hybrid closed loop system in type 1 diabetes: Impact on glycemic control and neuropsychological tests in the real world.
Amigó J; Ortiz-Zúñiga Á; de Urbina AMO; Sánchez M; Dos-Santos M; Abad M; Cuadra F; Simó R; Hernández C; Simó-Servat O
Diabetes Res Clin Pract; 2023 Jul; 201():110730. PubMed ID: 37236365
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of Hybrid Closed-Loop System in Adults with Type 1 Diabetes and Gastroparesis.
Kaur H; Schneider N; Pyle L; Campbell K; Akturk HK; Shah VN
Diabetes Technol Ther; 2019 Dec; 21(12):736-739. PubMed ID: 31347928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
